1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Rani Shares Positive Oral Ustekinumab Data After Last Year’s Challenges

RT-111 Oral Ustekinumab Biosimilar Passes Phase I Trial After Company Prioritization

 
• By Adam Zamecnik

Rani Therapeutics announced positive topline results from a Phase I trial of its oral Stelara biosimilar, moving it further in a crowded market with fierce competition.

Woman Taking Pill With Glass Of Water
The Oral Ustekinumab Biosimilar Passed Its Phase I Study • Source: Shutterstock

Rani Therapeutics has shared positive topline data from a Phase I trial of its orally administered biosimilar to Johnson & Johnson’s (J&J’s) Stelara (ustekinumab) known as RT-111 after undertaking strategic measures at the tail end of last year.

According to the San Diego, California-headquartered company, the biosimilar was well-tolerated among subjects recruited in the study, with no reports...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Reshaped Xbrane Allies With OneSource For Commercial Biosimilar Manufacturing

 
• By Dean Rudge

Xbrane Biopharma is partnering with India’s OneSource Specialty Pharma to manufacture its biosimilars, including its much-delayed ranibizumab product Ximluci. The move follows a SEK240m funding round and strategic refocus on commercialization after divesting key R&D assets to Alvotech.

Regeneron Monitoring Eylea Biosimilar Closely Following Innovative Setbacks

 
• By Dean Rudge

Regeneron says it is closely watching Amgen’s Pavblu 2mg aflibercept biosimilar, which is gaining traction via financial incentives to physicians as “the only differentiator” to its Eylea reference brand. Meanwhile, Regeneron is aiming to boost Eylea HD uptake amid regulatory setbacks.

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By Dave Wallace

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Formycon Snatches Brazilian Approval For Lucentis Biosimilar

 
• By Urtė Fultinavičiūtė

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.

More from Products